The starting point for negotiations with drug companies on prescription prices could end up being the too-high prices patients already live with.
CMS
Posted inHealth and Social Policy
Born to Die
Medicare spends tens of billions of dollars on hospice care each year. A new report ponders why regulators insist on going easy on literal death merchants.
Posted inHealth and Social Policy
Insurance Lobbyists Force Government to Heel on Medicare Advantage
But advocates see an opening for reining in the worst abuses of the program.
Posted inHealth and Social Policy
The Dark History of Medicare Privatization
Medicare Advantage was supposed to be a money-saver. It’s now become a costly, unaccountable cash cow for private insurance companies that is swallowing traditional Medicare.
Posted inHealth and Social Policy
Biden Regulators Take Action on Hidden Pharma Monopolies
A proposed rule would eliminate the ability of pharmacy benefit managers to extract profits after a prescription drug is sold.
Posted inCoronavirus
Unsanitized: Eighteen Deaths Per Hour in America’s Nursing Homes
Plus, more on the anti-police brutality protests, and what’s next for unemployment. This is The COVID-19 Daily Report for June 3, 2020.
Posted inEconomic Policy
Why the Justice Department Waved Through the CVS-Aetna Merger
The insurance company/pharmacy merger could have been fixed to prevent market power, even if it wasn’t totally blocked.